Hyperparathyroidism secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hyperparathyroidism}} | {{Hyperparathyroidism}} | ||
{{CMG}} | {{CMG}};{{AE}} {{Anmol}} | ||
==Overview== | ==Overview== | ||
Secondary prevention of primary hyperparathyroidism includes monitoring for potential progression of disease in patients who do not undergo parathyroidectomy. There are guidelines for monitoring of patients with asymptomatic hyperparathyroidism not undergoing parathyroidectomy. | Secondary prevention of primary hyperparathyroidism includes monitoring for potential progression of disease in patients who do not undergo [[parathyroidectomy]]. There are guidelines for monitoring of patients with asymptomatic hyperparathyroidism not undergoing [[parathyroidectomy]]. Effective measures for secondary prevention of secondary hyperparathyroidism include maintain adequate [[nutrition]], proper intake of [[vitamin D]] and/or sufficient sunlight exposure, and adequate [[physical activity]]. Effective measures for secondary prevention of tertiary hyperparathyroidism include early detection and treatment of hyperparathyroidism by either calcimimetics or [[parathyroidectomy]]. | ||
==Prevention== | |||
Secondary prevention of primary hyperparathyroidism includes monitoring for potential progression of disease in patients who do not undergo parathyroidectomy. There are guidelines for monitoring of patients with asymptomatic hyperparathyroidism not undergoing parathyroidectomy. These guidelines include:<ref name="pmid25162665">{{cite journal| author=Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C et al.| title=Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 10 | pages= 3561-9 | pmid=25162665 | doi=10.1210/jc.2014-1413 | pmc=5393490 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25162665 }}</ref> | ==Secondary Prevention== | ||
*'''Serum calcium''' | * Secondary prevention of primary hyperparathyroidism includes monitoring for potential progression of disease in patients who do not undergo [[parathyroidectomy]]. There are guidelines for monitoring of patients with asymptomatic hyperparathyroidism not undergoing [[parathyroidectomy]]. These guidelines include:<ref name="pmid25162665">{{cite journal| author=Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C et al.| title=Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. | journal=J Clin Endocrinol Metab | year= 2014 | volume= 99 | issue= 10 | pages= 3561-9 | pmid=25162665 | doi=10.1210/jc.2014-1413 | pmc=5393490 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25162665 }}</ref> | ||
**Serum [[calcium]] should be monitored annually. | **'''Serum calcium''' | ||
*'''Skeletal monitoring''' | ***Serum [[calcium]] should be monitored annually. | ||
**[[Dual energy X-ray absorptiometry|Dual-energy X-ray absorptiometry]] ([[Dual energy X-ray absorptiometry|DEXA]]) is used for [[Skeleton|skeletal]] monitoring. [[DEXA scan|DEXA]] should be done every 1-2 years (at 3 sites). | **'''Skeletal monitoring''' | ||
**X-ray or vertebral fracture assessment of [[spine]] may be done if indications are present such as height loss, and/or back pain. | ***[[Dual energy X-ray absorptiometry|Dual-energy X-ray absorptiometry]] ([[Dual energy X-ray absorptiometry|DEXA]]) is used for [[Skeleton|skeletal]] monitoring. [[DEXA scan|DEXA]] should be done every 1-2 years (at 3 sites). | ||
*'''Renal monitoring''' | ***X-ray or [[vertebral fracture]] assessment of [[spine]] may be done if indications are present such as height loss, and/or [[back pain]]. | ||
**Estimated [[glomerular filtration rate]] (eGFR) and [[serum creatinine]] should be done annually. | **'''Renal monitoring''' | ||
**24-hour [[biochemical]] [[Kidney stone|stone]] profile, [[Kidney|renal]] imaging by [[X-rays|x-ray]], [[ultrasound]], or [[CT scan]] may be considered if [[Kidney stone|renal stones]] are suspected. | ***Estimated [[glomerular filtration rate]] (eGFR) and [[serum creatinine]] should be done annually. | ||
***24-hour [[biochemical]] [[Kidney stone|stone]] profile, [[Kidney|renal]] imaging by [[X-rays|x-ray]], [[ultrasound]], or [[CT scan]] may be considered if [[Kidney stone|renal stones]] are suspected. | |||
* Effective measures for secondary prevention of secondary hyperparathyroidism include: | |||
**Maintain adequate [[nutrition]] | |||
**Proper intake of [[vitamin D]] and/or sufficient sunlight exposure | |||
**Adequate [[physical activity]] | |||
* Effective measures for secondary prevention of tertiary hyperparathyroidism include early detection and treatment of hyperparathyroidism by either calcimimetics or [[parathyroidectomy]]. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | {{WH}} | ||
{{WS}} | |||
[[Category:Disease]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Parathyroid disorders]] | [[Category:Parathyroid disorders]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
Latest revision as of 22:16, 29 July 2020
|
Hyperparathyroidism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hyperparathyroidism secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hyperparathyroidism secondary prevention |
|
Risk calculators and risk factors for Hyperparathyroidism secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
Secondary prevention of primary hyperparathyroidism includes monitoring for potential progression of disease in patients who do not undergo parathyroidectomy. There are guidelines for monitoring of patients with asymptomatic hyperparathyroidism not undergoing parathyroidectomy. Effective measures for secondary prevention of secondary hyperparathyroidism include maintain adequate nutrition, proper intake of vitamin D and/or sufficient sunlight exposure, and adequate physical activity. Effective measures for secondary prevention of tertiary hyperparathyroidism include early detection and treatment of hyperparathyroidism by either calcimimetics or parathyroidectomy.
Secondary Prevention
- Secondary prevention of primary hyperparathyroidism includes monitoring for potential progression of disease in patients who do not undergo parathyroidectomy. There are guidelines for monitoring of patients with asymptomatic hyperparathyroidism not undergoing parathyroidectomy. These guidelines include:[1]
- Serum calcium
- Serum calcium should be monitored annually.
- Skeletal monitoring
- Dual-energy X-ray absorptiometry (DEXA) is used for skeletal monitoring. DEXA should be done every 1-2 years (at 3 sites).
- X-ray or vertebral fracture assessment of spine may be done if indications are present such as height loss, and/or back pain.
- Renal monitoring
- Estimated glomerular filtration rate (eGFR) and serum creatinine should be done annually.
- 24-hour biochemical stone profile, renal imaging by x-ray, ultrasound, or CT scan may be considered if renal stones are suspected.
- Serum calcium
- Effective measures for secondary prevention of secondary hyperparathyroidism include:
- Maintain adequate nutrition
- Proper intake of vitamin D and/or sufficient sunlight exposure
- Adequate physical activity
- Effective measures for secondary prevention of tertiary hyperparathyroidism include early detection and treatment of hyperparathyroidism by either calcimimetics or parathyroidectomy.
References
- ↑ Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C; et al. (2014). "Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop". J Clin Endocrinol Metab. 99 (10): 3561–9. doi:10.1210/jc.2014-1413. PMC 5393490. PMID 25162665.